← Evidence map

ArticleiScience2026

Retraction notice to "SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma" [iScience 26 (2023) 106994].

Shanshan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Retraction notice to "SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma" [iScience 26 (2023) 106994]. | OpenQuestion